{
  "docId": "019de076-1fa8-714d-830b-c99557c4e3f8",
  "docSlug": "94eecf41575130a8334503229ea21cd4",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 26,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide displays 8 individual patient charts tracking biomarker levels over time, with specific annotations for NA retreatment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-1fa8-714d-830b-c99557c4e3f8/14",
  "deckHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8",
  "deckJsonHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8.json",
  "deckAnchorHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "chart",
      "text": "8 individual patient longitudinal charts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10277170-3881-48c3-8d1b-a2bbeab5ef93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "list",
      "text": "7 of 9 (78%) subjects remain off NA therapy for 44-64 weeks and all completed imdusiran treatment over 1½ years ago; Most subjects have maintained low HBV DNA levels off treatment; HBsAg remains between -0.8 and -1.6 log10 IU/mL below baseline values; NA discontinuation post-imdusiran treatment appears well tolerated with no ALT flares",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efeb3706-b381-4aba-981d-e3369ac94957",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.28,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "* Patient 53 restarted NA therapy for the NA d/c FU W20 visit (pink shaded area). ** Patient 58 restarted therapy after the NA d/c FU W36 visit (pink shaded area).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f10f305-6ef9-44b2-9a93-fc841e4ad592",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "AB-729-001: Imdusiran Shows Low Levels of HBV Biomarkers Persisting in cHBV Patients While Off-Treatment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5914683c-0498-40d2-abfe-ae085658ea51",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "19535154-91e5-4e57-a1b7-3e1d7891f13d",
      "evidence": "emphasis on unmet medical need and treatment benefits",
      "position": 0,
      "objective": "highlight the need for HBV treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}